2,790
Trials as lead sponsor
Most active programmes
The drugs appearing most often across Merck's recently active trials. Comparator arms are excluded.
- Pembrolizumab29 trials
- Sacituzumab tirumotecan15 trials
- Paclitaxel14 trials
- Carboplatin13 trials
- Rescue Medication9 trials
- MK-82948 trials
Upcoming readouts
Next primary completion dates among Merck's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
- Jun 2027A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-724…Phase 2
- Jul 2027A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembroliz…Phase 3
- Aug 2027Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)Phase 2
- Sept 2027A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants W…Phase 2
- Oct 2027A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004…Phase 2
- Oct 2027A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely A…Phase 2
Top therapeutic areas
Conditions studied most often across Merck's recently active trials.
- Non-small Cell Lung Cancer7 trials
- Malignant Neoplasm6 trials
- Ovarian Cancer4 trials
- Triple Negative Breast Neoplasms3 trials
- Bladder Cancer3 trials
- Breast Neoplasms3 trials
Merck pipeline by phase
The main study drugs across 226 active trials Merck leads on ClinicalTrials.gov. Each drug sits in the highest phase among its currently active trials, which can be lower than a phase it has already completed.
Phase 330 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Sacituzumab Tirumotecan | 17 | 10 | Jan 2027 est. | NCT07419295 · NCT07318558 · NCT06966700 |
| Belzutifan | 13 | 5 | Oct 2026 est. | NCT07489495 · NCT07405164 · NCT07227402 |
| CalderasibMK-1084 | 9 | 9 | Feb 2029 est. | NCT07554339 · NCT07431827 · NCT07190248 |
| 9vHPV VaccineV503 | 7 | — | Aug 2027 est. | NCT07785843 · NCT05450705 · NCT05314023 |
| Nemtabrutinib | 7 | 3 | Feb 2027 est. | NCT06136559 · NCT05947851 · NCT05624554 |
| Zilovertamab vedotin | 7 | 5 | Sept 2027 est. | NCT06717347 · NCT06890884 · NCT05458297 |
| Intismeran autogene | 6 | 4 | Jan 2028 est. | NCT06077760 · NCT05933577 · NCT07221474 |
| Tulisokibart | 6 | 3 | Jun 2027 est. | NCT06651281 · NCT07486960 · NCT07176390 |
| DOR/ISLMK-8591A | 5 | — | May 2029 est. | NCT05766501 · NCT05705349 · NCT05631093 |
| Enlicitide Decanoate | 5 | 2 | Dec 2026 est. | NCT07216482 · NCT06492291 · NCT06008756 |
| Patritumab deruxtecan | 5 | 5 | Dec 2028 est. | NCT07060807 · NCT06797635 · NCT06941272 |
| Raludotatug Deruxtecan | 5 | 3 | Mar 2029 est. | NCT07776691 · NCT07743164 · NCT06780098 |
| Bomedemstat | 4 | 1 | Jul 2027 est. | NCT06456346 · NCT06351631 · NCT06079879 |
| Ifinatamab Deruxtecan | 4 | 4 | Jun 2027 est. | NCT06925737 · NCT07630974 · NCT07405151 |
| MK-8527 | 4 | 2 | Oct 2026 est. | NCT07071623 · NCT07044297 · NCT07661108 |
| Opevesostat | 4 | 4 | Nov 2027 est. | NCT06136650 · NCT06136624 · NCT06979596 |
| Pembrolizumab (+) Berahyaluronidase alfa | 4 | — | Mar 2028 est. | NCT06698042 · NCT06504394 · NCT06099782 |
| Pembrolizumab 200 mg | 3 | — | Oct 2027 est. | NCT04624204 · NCT03765918 · NCT02861573 |
| IV Tulisokibart | 2 | 1 | Oct 2028 est. | NCT06430801 · NCT06052059 |
| MK-8748 | 2 | 1 | Oct 2028 est. | NCT07705607 · NCT07705555 |
| Pembrolizumab Formulated with Berahyaluronidase Alfa | 2 | — | — | NCT06212752 · NCT05722015 |
| Tapinarof cream, 1% | 2 | — | Oct 2026 est. | NCT07265479 · NCT05172726 |
| Intismeran | 1 | 1 | Aug 2034 est. | NCT07513376 |
| Molnupiravir | 1 | 1 | Jan 2031 est. | NCT06667700 |
| Pembrolizumab (K) | 1 | — | Jan 2031 est. | NCT03725059 |
| Pembrolizumab SC | 1 | — | — | NCT04956692 |
| Pembrolizumab/Vibostolimab Co-Formulation | 1 | — | — | NCT05224141 |
| Sacituzumab Govitecan | 1 | — | Jan 2027 est. | NCT05609968 |
| Suvorexant | 1 | 1 | Jun 2027 est. | NCT06655883 |
| V181 | 1 | 1 | Oct 2031 est. | NCT07013487 |
Phase 215 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| MK-1045 | 5 | 4 | Jul 2029 est. | NCT07709000 · NCT07634471 · NCT07570173 |
| ISL | 2 | 1 | Aug 2027 est. | NCT07266831 · NCT06891066 |
| MK-2010 | 2 | — | Sept 2028 est. | NCT07793942 · NCT07785609 |
| MK-7262 | 2 | 1 | Oct 2027 est. | NCT07614984 · NCT07619443 |
| Doravirine | 1 | 1 | Nov 2028 est. | NCT04375800 |
| Efinopegdutide | 1 | — | — | NCT06465186 |
| Frespaciguat | 1 | — | — | NCT05612035 |
| Miransertib | 1 | — | Feb 2030 est. | NCT04980872 |
| MK-2214 | 1 | 1 | Apr 2029 est. | NCT07033494 |
| MK-8690 | 1 | 1 | Oct 2027 est. | NCT07463183 |
| Olaparib | 1 | — | — | NCT03742895 |
| Pembrolizumab (neoadjuvant) | 1 | 1 | Feb 2032 est. | NCT06788912 |
| Posaconazole IV 6 mg/kg | 1 | 1 | Mar 2027 est. | NCT04665037 |
| Raludotatug Deruxtecan (R-DXd) | 1 | — | — | NCT06864169 |
| Vericiguat tablet | 1 | 1 | Apr 2032 est. | NCT05714085 |
Phase 125 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| MK-3120 | 3 | 3 | Oct 2028 est. | NCT07232602 · NCT07222488 · NCT06818643 |
| Gocatamig | 2 | 2 | Apr 2029 est. | NCT07227597 · NCT06780137 |
| MK-4082 | 2 | 1 | Sept 2026 est. | NCT07697625 · NCT07388667 |
| Ulonivirine | 2 | — | Jan 2027 est. | NCT07595263 · NCT05093972 |
| Coformulated favezelimab/pembrolizumab | 1 | — | May 2027 est. | NCT05845814 |
| coformulation pembrolizumab/quavonlimab | 1 | — | Dec 2029 est. | NCT04938817 |
| Letermovir | 1 | 1 | Apr 2028 est. | NCT07199465 |
| MK-0472 | 1 | — | Jun 2028 est. | NCT05853367 |
| MK-0616A | 1 | 1 | Oct 2026 est. | NCT07300280 |
| MK-1403 formulation (FM) 1 + additive | 1 | — | Sept 2026 est. | NCT07677163 |
| MK-1406 | 1 | — | Feb 2027 est. | NCT07743151 |
| MK-1484 | 1 | — | Sept 2026 est. | NCT05382325 |
| MK-4082 Formulation 1 (F1) | 1 | — | Dec 2026 est. | NCT07748351 |
| MK-4716 | 1 | 1 | Dec 2030 est. | NCT07247110 |
| MK-4884 | 1 | 1 | Oct 2029 est. | NCT07600749 |
| MK-8294 | 1 | 1 | Jul 2029 est. | NCT07030712 |
| Ramucirumab | 1 | 1 | May 2028 est. | NCT06445972 |
| Rosuvastatin | 1 | — | Nov 2026 est. | NCT07785830 |
| Tulisokibart Form 1 | 1 | — | — | NCT07405177 |
| V118C (Stage 1) | 1 | 1 | Oct 2028 est. | NCT07300267 |
| V118E | 1 | 1 | Jul 2027 est. | NCT07168915 |
| V132 Formulation 1 | 1 | 1 | Jun 2028 est. | NCT07712575 |
| V350A | 1 | 1 | Jul 2028 est. | NCT06655324 |
| V540B | 1 | 1 | May 2028 est. | NCT06623409 |
| V540D | 1 | — | Nov 2026 est. | NCT06688058 |
Phase 42 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| pembrolizumab | 35 | 12 | Nov 2026 est. | NCT07801027 · NCT07216703 · NCT06952504 |
| Sotatercept | 6 | 3 | Apr 2028 est. | NCT07600723 · NCT07218029 · NCT07646860 |
Combination backbones Paclitaxel (1 trial). Established agents these trials combine with, listed separately from the drugs under study.
Derived from 226 active trials Merck leads; 226 name an intervention, folding into 72 phased drugs. 1 intervention carries no registry phase (observational studies, tests and devices) and is not shown. This is ComplyRx's reading of the registry, not Merck's own pipeline disclosure.
Merck trials
The 50 most significant of Merck's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| A Clinical Trial of MK-1403 in Healthy Participants (MK-1403-007)NCT07677163MK-1403 formulation (FM) 1 + additive | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 15 est. | 22 Sept 2026 |
| A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021)NCT07661108MK-8527 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 44 est. | 9 Oct 2026 |
| Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)NCT03407144pembrolizumab | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 340 est. | 6 Nov 2026 |
| A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)NCT05319730Paclitaxel | Phase 1 | Locked · track to reveal | OngoingRecruiting | 230 est. | 11 Jun 2027 |
| A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)NCT07405151I-DXd | Phase 1 | Locked · track to reveal | OngoingRecruiting | 60 est. | 12 Jun 2027 |
| A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)NCT07133633Tulisokibart | Phase 2 | Locked · track to reveal | OngoingRecruiting | 315 est. | 15 Jun 2027 |
| A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)NCT06312176Sacituzumab tirumotecan | Phase 3 | Locked · track to reveal | OngoingRecruiting | 1,200 est. | 11 Jul 2027 |
| Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)NCT07486960Tulisokibart | Phase 2 | Locked · track to reveal | OngoingRecruiting | 140 est. | 13 Aug 2027 |
| A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)NCT05139017Zilovertamab vedotin | Phase 2 | Locked · track to reveal | OngoingRecruiting | 290 est. | 24 Sept 2027 |
| A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)NCT07614984MK-7262 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 750 est. | 12 Oct 2027 |
| A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)NCT07463183MK-8690 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 100 est. | 28 Oct 2027 |
| Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)NCT04624204Pembrolizumab 200 mg | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 672 est. | 28 Oct 2027 |
| A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038)NCT07821944Enlicitide Decanoate | Phase 3 | Not yet scored | OngoingNot yet recruiting | 150 est. | 26 Nov 2027 |
| A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)NCT06890884Zilovertamab vedotin | Phase 2 | Locked · track to reveal | OngoingRecruiting | 594 est. | 13 Dec 2027 |
| A Clinical Study of V503 in Chinese Females Who Have Previously Received a Bivalent Human Papillomavirus (HPV) Vaccine (V503-108)NCT07785843V503 | Phase 3 | Not yet scored | OngoingNot yet recruiting | 930 est. | 18 Dec 2027 |
| TroFuse-008Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)NCT06049212Sacituzumab tirumotecan | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 30 est. | 31 Dec 2027 |
| TroFuse-007Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)NCT06170788Sacituzumab tirumotecan | Phase 3 | Locked · track to reveal | OngoingRecruiting | 614 est. | 25 Jan 2028 |
| Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)NCT03998254V503 | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 6,000 est. | 31 Mar 2028 |
| A Clinical Study of V540A in Healthy Female Participants (V540A-005)NCT07224477V540A-2 | Phase 2 | Locked · track to reveal | StoppedWithdrawn | 0 est. | 4 Apr 2028 |
| A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)NCT07199465Letermovir | Phase 1 | Locked · track to reveal | OngoingRecruiting | 40 est. | 14 Apr 2028 |
| Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)NCT06445972Ramucirumab | Phase 1 | Locked · track to reveal | OngoingRecruiting | 210 est. | 9 May 2028 |
| Safety and Immunogenicity of V540B in Healthy Adults (V540B-002).NCT06623409GARDASIL®9 (G9) | Phase 1 | Locked · track to reveal | OngoingRecruiting | 72 est. | 31 May 2028 |
| A Study of V132 in Healthy Older Participants (V132-001)NCT07712575V132 Formulation 1 | Phase 1 | Not yet scored | OngoingRecruiting | 280 est. | 21 Jun 2028 |
| A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)NCT06925737Ifinatamab deruxtecan | Phase 3 | Locked · track to reveal | OngoingRecruiting | 1,440 est. | 26 Jun 2028 |
| OMAHA-003Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)NCT06136624Opevesostat | Phase 3 | Locked · track to reveal | OngoingRecruiting | 1,310 est. | 2 Aug 2028 |
| Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)NCT06305754Sacituzumab tirumotecan | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 550 est. | 17 Aug 2028 |
| A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)NCT06818643MK-3120 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 270 est. | 25 Oct 2028 |
| A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)NCT06430801IV Tulisokibart | Phase 3 | Locked · track to reveal | OngoingRecruiting | 1,200 est. | 30 Oct 2028 |
| A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)NCT07705555MK-8748 | Phase 3 | Not yet scored | OngoingRecruiting | 960 est. | 31 Oct 2028 |
| SOTERIAA Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)NCT07218029Sotatercept | Phase 3 | Locked · track to reveal | OngoingRecruiting | 815 est. | 7 Dec 2028 |
| Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]NCT06422143Pembrolizumab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 851 est. | 12 Jan 2029 |
| Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)NCT06353386Opevesostat | Phase 1 | Locked · track to reveal | OngoingRecruiting | 220 est. | 15 Jan 2029 |
| A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)NCT06345729Calderasib | Phase 3 | Locked · track to reveal | OngoingRecruiting | 600 est. | 19 Feb 2029 |
| A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)NCT07222488MK-3120 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 45 est. | 28 Feb 2029 |
| A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)NCT07266831ISL | Phase 2 | Locked · track to reveal | OngoingRecruiting | 570 est. | 21 Mar 2029 |
| A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)NCT06843447Raludotatug Deruxtecan | Phase 1 | Locked · track to reveal | OngoingRecruiting | 605 est. | 27 Mar 2029 |
| A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)NCT06997497Calderasib | Phase 3 | Locked · track to reveal | OngoingRecruiting | 477 est. | 28 Mar 2029 |
| Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)NCT06395103Zilovertamab vedotin | Phase 1 | Locked · track to reveal | OngoingRecruiting | 90 est. | 31 Mar 2029 |
| A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)NCT06824467Sacituzumab tirumotecan | Phase 3 | Locked · track to reveal | OngoingRecruiting | 770 est. | 27 Apr 2029 |
| A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)NCT06780137Gocatamig | Phase 1 | Locked · track to reveal | OngoingRecruiting | 327 est. | 27 Apr 2029 |
| A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032)NCT07646860Sotatercept | Phase 2 | Not yet scored | OngoingRecruiting | 6 est. | 24 May 2029 |
| A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)NCT07030712MK-8294 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 67 est. | 1 Jul 2029 |
| A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)NCT06717347Zilovertamab vedotin | Phase 3 | Locked · track to reveal | OngoingRecruiting | 1,046 est. | 2 Jul 2029 |
| A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)NCT07363590MK-1045 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 21 est. | 16 Jul 2029 |
| TroFuse-031A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)NCT07419295Sacituzumab tirumotecan | Phase 3 | Locked · track to reveal | OngoingRecruiting | 590 est. | 27 Jul 2029 |
| A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)NCT07286149MK-1084 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 140 est. | 17 Aug 2029 |
| Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)NCT06469944Pembrolizumab | Phase 1 | Locked · track to reveal | OngoingRecruiting | 160 est. | 12 Sept 2029 |
| Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)NCT07600749MK-4884 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 120 est. | 4 Oct 2029 |
| A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)NCT06428409Sacituzumab tirumotecan | Phase 1 | Locked · track to reveal | OngoingRecruiting | 220 est. | 16 Oct 2029 |
| KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)NCT07252739MK-1084 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 140 est. | 15 Nov 2029 |